Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.983 SEK | +3.22% | -24.88% | -60.77% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Sales 2023 | 35.2M 3.23M | Sales 2024 * | 105M 9.66M | Capitalization | 285M 26.23M |
---|---|---|---|---|---|
Net income 2023 | -249M -22.88M | Net income 2024 * | -244M -22.42M | EV / Sales 2023 | 18.7 x |
Net cash position 2023 | 66.92M 6.15M | Net cash position 2024 * | 208M 19.08M | EV / Sales 2024 * | 0.74 x |
P/E ratio 2023 |
-2.78
x | P/E ratio 2024 * |
-1.89
x | Employees | 57 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.37% |
Latest transcript on Oncopeptides AB
1 day | +3.22% | ||
1 week | -24.88% | ||
Current month | -53.77% | ||
1 month | -43.07% | ||
3 months | -55.72% | ||
6 months | -57.07% | ||
Current year | -60.77% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.005 | +3.98% | 834 996 |
24-04-25 | 2.89 | -10.25% | 2,636,199 |
24-04-24 | 3.22 | +2.06% | 2,526,246 |
24-04-23 | 3.155 | -11.62% | 1,053,101 |
24-04-22 | 3.57 | -10.75% | 763,366 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 06:19 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.77% | 26.17M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.20% | 22.02B | |
-17.84% | 20.9B | |
-9.21% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- ONCO Stock